What factors drove the changes in Alkermes's revenue and profit?

What is Alkermes's gross profit margin?

What is Alkermes's latest dividend and current dividend yield?

What guidance did Alkermes's management provide for the next earnings period?

What does Alkermes do and what are its main business segments?

What is the market's earnings forecast for Alkermes next quarter?

What were the key takeaways from Alkermes’s earnings call?

What were the key takeaways from Alkermes's earnings call?

- **2026 Growth Ambition**: $1.7B+ revenue, $370M+ EBITDA, driven by LUMRYZ ($350M+), alixorexton Phase III, and ADHD/fatigue pipeline.
- **Alixorexton Milestone**: Phase III in narcolepsy to start Q2, targeting split dosing for extended wakefulness.
- **Avadel Synergy**: LUMRYZ adds sleep medicine expertise, with 2026 net sales guidance of $350-$370M.
- **Pipeline Expansion**: ALKS 7290 ADHD Phase Ib and ALKS 4510 fatigue Phase IIa to begin 2026, alongside valiloxybate development.
- **Leadership Transition**: Richard Pops remains Chairman, Blair Jackson becomes CEO, positioning for long-term growth.

**【CEO Summary Section】**
- 2026 revenue target: $1.73-$1.84 billion, with adjusted EBITDA of $370-$410 million.
- Avadel acquisition adds LUMRYZ, a once-nightly sodium oxybate, with 2025 net sales of $279 million.
- Alixorexton Phase III in narcolepsy (Brilliance program) to start Q2 2026, targeting NT1 and NT2 with split dosing options.
- Leadership transition: Richard Pops to remain Chairman, Blair Jackson becomes CEO effective summer 2026.

**【CFO Financial Commentary】**
- 2025 total revenue: $1.5 billion (9% YoY growth), with proprietary products at $1.18 billion.
- 2026 financial outlook: GAAP net loss $115-$135 million, adjusted EBITDA $370-$410 million.
- Key expenses: R&D ($445-$485M), SG&A ($890-$930M), including $50M Avadel transaction costs.
- LUMRYZ contribution: $350-$370M in 2026, with 6 weeks of post-acquisition revenue at $33M.

**【CCO Commercial Update】**
- VIVITROL: 2026 net sales $460-$480M, ARISTADA $365-$385M, LYBALVI $380-$400M.
- LUMRYZ: 3,500 patients as of Q4 2025, targeting 50,000 eligible narcolepsy patients.
- LUMRYZ Phase III for idiopathic hypersomnia (REVITALIZE) expected to report Q2 2026.
- Integration of Avadel's sleep medicine commercial team underway.

**【Pipeline Update】**
- Alixorexton: Phase III in narcolepsy with split dosing, Phase II in idiopathic hypersomnia (Vibrance-3) to complete Q4 2026.
- ALKS 7290: ADHD Phase Ib study to start H2 2026, targeting attention and impulsivity.
- ALKS 4510: Fatigue in MS/Parkinson's Phase IIa to start 2026.
- Valiloxybate: Sodium-free oxybate candidate in early clinical development.

**【Q&A Highlights】**
- Split dosing for alixorexton: Designed to extend wakefulness without increasing AE burden.
- LUMRYZ vs. generics: Once-nightly differentiation maintains >90% payer access.
- ADHD strategy: ALKS 7290 Phase II to test efficacy in unenriched ADHD population.
- Synergies: Separate sales forces for psychiatry and sleep medicine, potential integration post-alixorexton launch.
- Valiloxybate: Potential replacement for LUMRYZ if bioequivalence achieved.


Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript

- **Acquisition of Avadel**: Adds LUMRYZ to diversify portfolio, with 2025 revenue of $265–$275 million.
- **Revenue Growth**: Q3 proprietary products up 16% to $317.4 million; full-year guidance raised to $1.43–$1.49 billion.
- **Pipeline Momentum**: Alixorexton NT1 Phase II data positive; NT2 data due in November with potential Phase III start in Q1 2026.
- **Product Performance**: VIVITROL, ARISTADA, and LYBALVI all exceed prior guidance, with LYBALVI TRx growth 25% YoY.
- **Financial Strength**: Q3 GAAP net income $82.8 million; EBITDA $96.9 million, with strong cash position ($1.14 billion).

**【CEO Opening Remarks】**
- Announced the proposed acquisition of Avadel Pharmaceuticals, adding LUMRYZ (FDA-approved oxybate) to diversify the portfolio and enter the sleep medicine market. Expected 2025 revenue contribution: $265–$275 million.
- Highlighted progress in the orexin receptor agonist pipeline, including alixorexton Phase II data in narcolepsy type 1 (NT1) and upcoming NT2 data in November.
- Raised full-year 2025 guidance: Total revenues $1.43–$1.49 billion, GAAP net income $230–$250 million, EBITDA $270–$290 million.

**【CFO Financial Commentary】**
- Q3 2025 total revenues: $394.2 million (16% YoY growth in proprietary products to $317.4 million).
- Gross-to-net favorability: $8 million (VIVITROL) and $5 million (ARISTADA) due to Medicaid utilization.
- R&D expenses: $81.7 million (investing in alixorexton Phase II and new orexin candidates ALKS 4510/7290).
- Q4 2025 proprietary product net sales guidance: $300–$320 million.

**【Commercial Update】**
- **VIVITROL**: Q3 net sales $121.1 million, full-year guidance raised to $460–$470 million. Driven by alcohol dependence market growth.
- **ARISTADA**: Q3 net sales $98.1 million, full-year guidance $360–$370 million. New-to-brand prescriptions and prescriber breadth increasing.
- **LYBALVI**: Q3 net sales $98.2 million (32% YoY growth), full-year guidance $340–$350 million. TRx growth 25% YoY, gross-to-net 28%.

**【Q&A Highlights】**
- **LYBALVI**: Strong TRx growth (25% YoY) due to expanded sales force. Q4 gross-to-net expected to rise slightly, but full-year guidance maintained.
- **Alixorexton NT2**: Phase II data expected in November; potential Phase III launch Q1 2026. Focus on dose response and safety in NT2 vs. NT1.
- **Policy Impact**: Medicaid utilization dynamics drove Q3 favorability, but no additional benefits expected in Q4.
- **Pipeline Expansion**: ALKS 4510/7290 Phase I studies progressing; no-salt oxybate (valiloxybate) in early development.

Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript

- **Q2 Financial Success**: Proprietary product sales up 14% YoY to $307.2 million, driven by strong demand across VIVITROL, ARISTADA, and LYBALVI.
- **Breakthrough Orexin Data**: Alixorexton Phase II study shows significant improvement in wakefulness, fatigue, and cognition in NT1, with no safety red flags.
- **Pipeline Expansion**: ALKS 4510 and 7290 entering clinical development, expanding orexin receptor applications beyond narcolepsy.
- **Financial Strength**: $1.05 billion cash, no debt, and on track for >$1 billion proprietary product sales in 2025.
- **Strategic Focus**: Accelerating Phase III planning for alixorexton, with NT2 data expected to shape registrational strategy.

**【CEO Summary Section】**
- Reported strong Q2 performance with proprietary product net sales of $307.2 million, up 14% YoY, driven by VIVITROL, ARISTADA, and LYBALVI growth.
- Announced positive top-line results from the Vibrance 1 Phase II study of alixorexton in narcolepsy type 1, showing significant improvement in wakefulness, fatigue, and cognition with a favorable safety profile.
- Highlighted strategic pipeline expansion with ALKS 4510 and ALKS 7290 entering clinical development for orexin receptor agonists beyond narcolepsy.
- Emphasized financial strength with $1.05 billion in cash and no debt, supporting future growth initiatives.

**【CFO Financial Commentary】**
- Total Q2 revenue: $390.7 million, including $307.2 million from proprietary products and $83.4 million from manufacturing/royalty.
- GAAP net income: $87.1 million; adjusted EBITDA: $126.5 million.
- R&D expenses: $77.4 million (up 29.8% YoY) due to alixorexton Phase II studies; SG&A: $170.8 million (1.7% YoY increase).
- Guidance: On track for record proprietary product net sales (~$1 billion) and profitability in 2025.

**【CCO (Commercial) Update】**
- VIVITROL net sales: $121.7 million (14% YoY growth); ARISTADA: $101.3 million (13% YoY); LYBALVI: $84.3 million (18% YoY growth).
- LYBALVI TRx growth: 22% YoY, with gross-to-net adjustments at ~30%.
- Expanded psychiatry sales force driving ARISTADA new-to-brand prescriptions and prescriber breadth.

**【CMO (Medical) Update】**
- Vibrance 1 Phase II study: Alixorexton demonstrated statistically significant improvement in wakefulness (MWT), excessive daytime sleepiness (ESS), and cataplexy at 6 mg dose.
- Exploratory endpoints (fatigue, cognition) showed robust improvement, supporting broader orexin receptor utility.
- Safety: Generally well-tolerated with no treatment-emergent serious adverse events; no visual AE signals detected.
- Vibrance 2 (NT2) and Vibrance 3 (IH) Phase II studies progressing, with NT2 expected to complete enrollment soon.

**【Q&A Highlights】**
- **Visual AEs**: No concerning signals; ophthalmic exams showed no changes; Phase III will use refined statistical methods to minimize variability.
- **Regulatory Path**: Planning Phase III program post-NT2 data; seeking label for narcolepsy writ large (NT1/NT2).
- **Pipeline Risk**: ALKS 4510 and 7290 may have differentiated PK profiles, but human data needed to confirm AE profiles.
- **Competitive Edge**: Dose flexibility (4-8 mg in NT1) and broader symptom improvement (cognition/fatigue) differentiate alixorexton.
- **Label Claims**: Cataplexy inclusion likely based on data trends; Phase III will optimize endpoints for regulatory approval.

Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript

- **Commercial Momentum**: LYBALVI sales +23% YoY, VIVITROL alcohol dependence share 75%, ARISTADA sales $73.5M.
- **Orexin Pipeline**: ALKS 2680 Phase 2 data expected Q3 (NT1), mid-2025 (NT2), with Vibrance-3 (IH) starting Q2.
- **Financial Strength**: $916M cash, 5% YoY R&D growth, 4% YoY SG&A savings.
- **Regulatory Readiness**: Preparing for Phase 3 with broad dose range and clinical trial network.
- **Macro Resilience**: U.S.-only manufacturing mitigates tariff risk; <5% VIVITROL sales from Medicaid.


**【CEO Opening Remarks】**
- Alkermes is on track to meet 2025 financial guidance, with Q1 proprietary product sales up 5% YoY to $244.5M, driven by LYBALVI growth.
- Emphasized focus on orexin receptor agonist ALKS 2680 Phase 2 program in narcolepsy, with Vibrance-1 (NT1) enrollment complete and data expected Q3 2025.
- Highlighted U.S.-based manufacturing advantage in mitigating macroeconomic risks like tariffs and foreign reference pricing.

**【Todd Nichols - Commercial Update】**
- LYBALVI net sales grew 23% YoY to $70M, with TRx up 22%, driven by schizophrenia and bipolar I disorder indications.
- VIVITROL net sales $101M, 75% from alcohol dependence indication; 2025 guidance $440-460M.
- ARISTADA net sales $73.5M; 2025 guidance $335-355M.
- Psychiatry sales force expansion completed, targeting ARISTADA reacceleration.

**【Blair Jackson - Financial Review】**
- Q1 GAAP net income $22.5M, EBITDA $22.8M, adj. EBITDA $45.6M.
- R&D expenses $71.8M (+6% YoY) for ALKS 2680 Phase 2 studies.
- SG&A $171.7M (-4% YoY) due to promotional efficiency.
- Cash balance $916.2M; $200M share buyback authorization remains.

**【Craig Hopkinson - R&D Update】**
- ALKS 2680 Phase 2 program on track:
  - Vibrance-1 (NT1) enrollment complete, data Q3 2025.
  - Vibrance-2 (NT2) mid-2025 enrollment, data fall 2025.
  - Vibrance-3 (idiopathic hypersomnia) initiated Q2 2025.
- Project Saturn: ALKS 4510 and ALKS 7290 first-in-human studies expected 2025 H2.

**【Key Q&A Highlights】**
- ALKS 2680 safety: No protocol modifications from DSMB; visual disturbances rare and transient.
- LYBALVI vs. COBRENTIS: No trade-off seen; 55% of LYBALVI scripts for bipolar I.
- Medicaid impact: <5% of VIVITROL sales from government OD funding.
- Orexin franchise: Potential for multiple Phase 3 indications based on Phase 2 PROs.


Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript

- **Record 2024 Financials**: $1.5B+ revenue, $452M EBITDA, debt-free balance sheet with $825M cash.
- **Orexin 2680 Pivotal Year**: 160-patient Phase 2 narcolepsy studies to read out H2 2025, with Phase 3 potential soon after.
- **LYBALVI Growth Engine**: 25%+ 2025 demand growth, 80 new reps, mid-30s gross-to-net rate.
- **2025 EBITDA Target**: $200+ million, with Q1 near breakeven due to seasonal factors.
- **Pipeline Investment**: $200M+ annual R&D to advance orexin receptor agonists.

**【CEO Summary Section】**
- **2024 Financial Highlights**: Total revenue exceeded $1.5 billion, with proprietary portfolio growing 18% YoY. EBITDA from continuing operations reached $452 million, and the company ended the year debt-free with $825 million in cash.
- **2025 Outlook**: Targeting $200+ million EBITDA, with focus on orexin program ALKS 2680. Phase 2 studies in narcolepsy (160 patients) expected to complete in H2 2025, with potential Phase 3 initiation shortly thereafter.
- **Pipeline Investment**: $200 million+ annual R&D spend to advance ALKS 2680, ALKS 4510, and ALKS 7290, positioning as leader in orexin receptor agonist therapeutics.

**【CFO Financial Commentary】**
- **2024 Financials**: GAAP net income $372 million, non-GAAP net income $494 million. COGS reduced 3% YoY to $245 million, R&D expenses $245 million, SG&A $645 million.
- **2025 Guidance**: Total revenue $1.34-1.43 billion (proprietary products $1.09-1.15 billion). EBITDA $215-245 million, adjusted EBITDA $310-340 million. Q1 2025 EBITDA near breakeven due to seasonal inventory normalization.
- **Cash Position**: $825 million ending 2024, with $200 million share buyback authorization remaining.

**【Commercial Portfolio Update】**
- **VIVITROL**: 14% YoY net sales growth ($457 million), 75% of volume in alcohol dependence. 2025 demand growth expected mid-single digits.
- **LYBALVI**: 46% YoY growth ($280 million), 25%+ 2025 demand growth driven by 80 new sales reps. Gross-to-net rate expected mid-30s.
- **ARISTADA**: 6% YoY growth ($346 million), stable performance in competitive antipsychotic market.

**【Q&A Key Takeaways】**
- **Orexin Safety & Tolerability**: Phase 2 studies designed with 80-patient arms, 6-week double-blind period. DSMB monitoring safety; no significant retention issues noted.
- **Sales Force Expansion**: 80 new reps added Q1 2025, targeting LYBALVI and ARISTADA. Expected contribution in Q3+ 2025.
- **Policy Risks**: Medicaid reforms could impact access, but schizophrenia/bipolar drugs not major cost drivers. Medicare Part D 1% rebate threshold maintained.
- **Competitive Dynamics**: Orexin 2 receptor agonist class excitement growing; ALKS 2680 differentiated by dose flexibility and real-world patient focus.


Actual											0.0093	0.0558	0.2417	0.093	0.1023	0.2789	0.1301	0.2138	0.1116	0.0558	0.0186	0.1301	0.0093	0.5113	0.5949	0.22	0.43	0.7	0.72	1.05	0.2652	0.6683	0.6843	0.4677
Forecast											-0.0434	0.0059	0.0019	0.0617	-0.0139	0.1099	0.0582	0.0743	0.0232	0.0066	0.0277	0.0419	0.0045	0.3672	0.396	0.4474	0.5827	0.704	0.7205	0.7712	0.2545	0.38	0.3688	0.4102
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+121.43%	+845.76%	+12621.05%	+50.73%	+835.97%	+153.78%	+123.54%	+187.75%	+381.03%	+745.45%	-32.85%	+210.50%	+106.67%	+39.24%	+50.23%	-50.83%	-26.21%	-0.57%	-0.07%	+36.15%	+4.20%	+75.87%	+85.55%	+14.02%

ALKS

ALKS fundamentals

ALKS Q4 2025 Earnings

Earnings Call

You can ask Aime

ALKS

ALKS fundamentals

ALKS Q4 2025 Earnings

Earnings Call

ALKS Earnings Call Summary for Q4/20259:00 AM on Feb 25, 2026

ALKS Earnings Call Summary for Q3/20258:00 AM on Oct 28, 2025

ALKS Earnings Call Summary for Q2/20258:00 AM on Jul 29, 2025

ALKS Earnings Call Summary for Q1/20258:00 AM on May 1, 2025

ALKS Earnings Call Summary for Q4/20248:00 AM on Feb 12, 2025

You can ask Aime